Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sahil Narkhede"'
Autor:
Daniel M. Halperin, Lynn Huynh, Jennifer L. Beaumont, Beilei Cai, Rachel H. Bhak, Sahil Narkhede, Todor Totev, Mei S. Duh, Maureen P. Neary, David Cella
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background There is limited information on changes over time in carcinoid syndrome (CS) symptoms and quality of life (QoL). This study assessed change in CS symptoms and QoL in patients treated with somatostatin analogs (SSAs) using the Func
Externí odkaz:
https://doaj.org/article/825c2e89b3464011b03ad494c1c9646b
Autor:
David Cella, Beilei Cai, Jennifer L. Beaumont, Lynn Huynh, Todor Totev, Daniel M. Halperin, Maureen P. Neary, Rachel H. Bhak, Mei Sheng Duh, Sahil Narkhede
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer
BMC Cancer
Background There is limited information on changes over time in carcinoid syndrome (CS) symptoms and quality of life (QoL). This study assessed change in CS symptoms and QoL in patients treated with somatostatin analogs (SSAs) using the Functional As
Autor:
Yinong Young-Xu, Patrick Lefebvre, Dominic Pilon, Sophia Li, Stephen J. Freedland, Sahil Narkhede, Rachel H. Bhak
Publikováno v:
Current medical research and opinion. 37(4)
To quantify the association between dose reductions of abiraterone acetate plus prednisone (AAP) or enzalutamide and prostate-specific antigen (PSA) progression in patients with metastatic castration-resistant prostate cancer (mCRPC). Changes in medi
Autor:
Estella Mendelson, Sahil Narkhede, Darshan Dalal, Patricia Brandt, Mei Sheng Duh, Lynn Huynh, Diego Cortina, Jorge E. Cortes, Maral DerSarkissian
Publikováno v:
Leukemialymphoma. 61(1)
Achievement of MR4.5 (BCR-ABL1 ≤ 0.0032% on international scale) is an important goal of tyrosine kinase inhibitor (TKI) treatment for patients with chronic myeloid leukemia (CML). This study describes treatment patterns by region and assesses time
Autor:
Halperin, Daniel, Huynh, Lynn, Beaumont, Jennifer, Beilei Cai, Bhak, Rachel, Sahil Narkhede, Totev, Todor, Duh, Mei, Neary, Maureen, Cella, David
Table S1. Change in Quality of Life Scores between Time Point 1 and Time Point 2: New CS-specific FACT-G Subscale. Table S2. Change in Quality of Life Scores between Time Point 1 and Time Point 2 for Participants with Carcinoid Syndrome: PROMIS-29 an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cace5f12567f211d8b219bfe6ffeef4
Autor:
Patrick Lefebvre, Alexander D. Fuld, Yinong Young-Xu, Dominic Pilon, Sahil Narkhede, Ajay S. Behl, Sophia Li, Rhiannon Kamstra, Rachel H. Bhak, Stephen J. Freedland
Publikováno v:
Journal of Urology. 199
Autor:
Rachel H. Bhak, Mei Sheng Duh, Maureen P. Neary, David Cella, Beilei Cai, Jennifer L. Beaumont, Sahil Narkhede, Daniel M. Halperin, Lynn Huynh
Publikováno v:
Journal of Clinical Oncology. 36:400-400
400 Background: Limited information is available on the longitudinal impact of CS symptoms and QoL in CS patients (pts) who received SSAs in real-world setting. This study aimed to examine change in CS symptoms and QoL in CS pts treated with SSAs usi